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1 |  INTRODUCTION
Fabry disease (FD) (OMIM 301500) is an X‐linked disor-
der of glycosphingolipid catabolism caused by a deficiency 
of the lysosomal enzyme alpha‐galactosidase A (GLA). 
This enzymatic defect leads to a chronic and progressive 
systemic accumulation of glycosphingolipids, mainly glo-
botriaosylceramide, in lysosomes of cells of different tis-
sues. Clinical presentation in classical Fabry hemizygous 
males may present during childhood or adolescence with 
acroparesthesia, anhidrosis, angiokeratoma, cornea ver-
ticillata, gastrointestinal symptoms, and microalbumin-
uria. At a later age, progressive renal failure, hypertrophic 
cardiomyopathy and cerebrovascular disease can occur, 
reducing life expectancy (Mehta et al., 2004). Most hetero-
zygous women are also affected, but demonstrate a more 
variable phenotype. Later onset forms of FD also occur, 
with signs and symptoms usually presenting at an adult 
age and generally restricted to one main affected organ 
(Doheny et al., 2018).
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Abstract
Background: Fabry disease (FD) is an X‐linked disorder of glycosphingolipid ca-
tabolism caused by a deficiency of the lysosomal enzyme alpha‐galactosidase A 
(GLA). FD is still an underdiagnosed disorder worldwide. Moreover, there is delay 
between symptom onset and Fabry diagnosis of at least 10 years. Family screening 
offers an important benefit for detection of new patients. The aim of this work is to 
present the approach along with the results of a targeted genetic strategy for pedigree 
analysis for FD in Argentina.
Methods: By this strategy as soon as a new index Fabry patient is diagnosed, the 
pedigree group contacts the physician and a meeting is arranged with the physician 
and the family to build the family tree.
Results: Pedigree analysis was carried out for full in 31 families. In the work period, 
we have tested 1,462 relatives, and 501 were diagnosed FD. The proportion of posi-
tive detection was 33%.
Conclusion: The targeted family screening approach is successful to detect undi-
agnosed Fabry patients. By this approach, the highest ratio index to pedigree ever 
reported for FD pedigree analysis of 1:15 was obtained.
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Diagnosis of FD patients generally starts by clinical sus-
picion by physicians based on clinical examination of the 
patient, his medical and family history. Laboratory confirma-
tory diagnosis of FD in males is carried out by determination 
of GLA activity in leukocytes, followed by mutation analysis; 
on the other hand only genetic test is useful for diagnosis in 
females.
The estimated prevalence is around 1:40,000 to 1:117,000 
males (Meikle, Hopwood, Clague, & Carey, 1999; Poorthuis 
et al., 1999). However, a pilot newborn screening study 
showed a much higher incidence of 1 of 3,600 (Spada et al., 
2006). This difference implies FD is still an underdiagnosed 
disorder worldwide. Moreover, there is delay between symp-
tom onset and Fabry diagnosis of at least 10 years (Reisin, 
Perrin, & García‐Pavía, 2017). Other strategies to detect still 
undiagnosed patients is through at risk screenings (Linthorst 
et al., 2010) and family screening (Rozenfeld, Ceci, Roa, & 
Kisinovsky, 2015).
Family screening offers an important benefit for detection 
of new patients. Diagnosis by family screening has the poten-
tial of diagnose relatives at an earlier age as compared as if 
the patients would have been diagnosed by clinical suspicion.
The aim of this work is to present the approach along with 
results of a targeted genetic strategy for pedigree analysis for 
FD in Argentina.
2 |  ACTIVITIES OF THE 
PEDIGREE GROUP
A program for targeted genetic approach was carried out in 
order to offer assistance in pedigree analysis to the physicians 
who have diagnosed a Fabry index case. The study period is 
from April 2003 to November 2018. The program is carried 
out by a multidisciplinary group consisting of social worker, 
geneticist, and biochemist.
As soon as a new index Fabry patient is diagnosed, the 
pedigree group contacts the physician in order to offer him 
the assistance by the pedigree program group. After authori-
zation by the physician a meeting is arranged with the group, 
the physician, and the family. In this meeting the index case 
or other members of the family are asked to provide informa-
tion of the family and to build together the family tree.
The first step is to analyze if the mutation in the index case 
is de novo or inherited. For this task we ask for samples of 
the parents of the index case. If the mutation is present in the 
family, we continue analyzing the family tree. As the family 
tree is being done, the biochemist and geneticist guide doctor 
on which family member has a risk to be affected due to X‐
linked inheritance. The family screening is done step by step, 
from old members first and then going down in the tree of the 
positive relatives that are being detected.
In several cases, the family relatives live far away from the 
index case. The mapping is done by social worker who makes 
connections, investigates, visit different locations looking for 
other members of family.
Blood samples were collected by venipuncture. We re-
ceived dried blood spots from male patients for enzymatic 
activity assay. If the result is pathologic, 10  ml of heparin 
blood in order to confirm the diagnosis by measuring GLA 
activity in leukocytes. EDTA blood was received from female 
patients for genetic test, and also from male Fabry patients 
diagnosed by deficient GLA activity in leukocytes.
The procedures followed were in accordance with the 
ethical standards of the Ethical Committee of AADELFA 
(CABA, Argentina) and with the Helsinki Declaration of 
1975, as revised in 2013. All patients provided written in-
formed consent to participate in this study.
3 |  ENZYMATIC ACTIVITY 
DETERMINATION
The GLA activity determination was carried out on dried blood 
filter paper or leukocytes, according to the method of Chamoles, 
Blanco, and Gaggioli (2001) and described in Ceci et al. (2011).
4 |  MUTATION DETECTION IN 
GL A  GENE
Mutation analysis of GLA gene (NG_007119.1) was done 
using DNA isolated from EDTA blood samples. Polymerase 
T A B L E  1  Type of mutation detected in the 36 families







T A B L E  2  The table shows the number of female, male and total relatives studied from the 31 families, and the number of positive cases. In 
this table, the index cases are included in the numbers
Female studied Female positive Male studied Male positive Total studied Total positive
895 339 567 162 1,462 501
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chain reaction amplification of specific exon by the use of 
specific primers was carried out. The amplicons were purified 
and then sequenced in both directions in a DNA Sequencing 
device (Applied Biosystems, Foster City, California).
In the period we have worked with 36 different Fabry fam-
ilies. Each family has a different mutation. Type of mutation 
detected is represented in Table 1. The most frequent are the 
missense mutations, accounting for 64% of them, followed 
by deletion and nonsense mutations. Insertions and splicing 
were the less frequent.
The first part of the work consisted of analyzing if the mu-
tation is inherited or de novo. In 5 of the families (14%), the 
mutation was de novo. In this 5 families, pedigree analysis 
was carried only with the descendants of the index case. In 
only 1 family (N° 19) there were descendants, we studied 3 
daughters from the index case who were heterozygotes.
So, pedigree analysis was carried out for full in 31 fam-
ilies in which the mutation was inherited by the index case. 
In the work period, we have tested 1,462 relatives, and 501 
were diagnosed FD (Table 2). The proportion of positive de-
tection was 33%. The ratio index to pedigree is 1:15, it means 
for each index case we detected 15 more Fabry patients in 
average by this pedigree analysis program. This number em-
phasizes even more the great success of this approach. As 
can be observed the number of heterozygotes is the double 
of hemizygotes, which is characteristic due to the X‐linked 
inheritance of this disorder.
We obtained a high proportion of positive cases detection. 
The reasons are numerous:
1. The use of a targeted genetic approach versus at ran-
dom analysis. Pedigree analysis in this work was done 
generation by generation in a stepwise mode, analyzing 
each time the risk of each patient of having inherited 
the mutation. We have analyzed only at risk cases. In 
this way we avoided testing relatives who have no risk 
at all such as children of normal parents or sons from 
affected males.
2. Pedigree tree: The social worker in the pedigree analysis 
team had a central role. Her work is to contact the relatives 
who have a greater knowledge of the family. It let us to 
build a more complete and expanded tree.
3. Distances: we could contact relatives living far away from 
the index case in our vast country. For example, in family 
4, there were relatives living 3,000 kilometers far away. In 
other families, there are relatives living in 3 or more dif-
ferent provinces.
4. Assistance to the index case physician: In most of the 
cases, physicians of the index cases are nephrologists 
or cardiologists. They do not have experience in genetic 
 diseases and how to carry out pedigree analysis and 
 genetic counseling. Moreover, generally, they do not have 
enough time in their consultant to work with the family. 
The assistance of the pedigree team, who works in close 
contact with him, gives him the possibility to have the 
whole family diagnosed.
There is no vast information on pedigree analysis in FD. Few 
experiences of pedigree analysis are reported in literature, 
with variable ratios between 1:2 and 1:13. In this work, to 
our knowledge we are reporting the highest ratio of pedigree 
analysis for FD of 1:15. The ratio of 1:13 was reported in a 
work with only 2 families (Maron et al., 2018).
In conclusion, the targeted family screening approach is 
successful to detect undiagnose Fabry patients. By this ap-
proach, the highest ratio ever reported of 1:15 was obtained.
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